The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor

The Effect of Cell Surface Expression and Linker Sequence on the Recruitment of Arrestin to the GIP Receptor

The glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1) receptor are important targets in the treatment of both type 2 diabetes mellitus (T2DM) and obesity. Originally identified for their role in desensitization, internalization and recycling of G protein-coup...

Full description

Bibliographic Details
Main Authors:	Suleiman Al-Sabah, Lobna Adi, Moritz Bünemann, Cornelius Krasel
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-08-01
Series:	Frontiers in Pharmacology
Subjects:	G protein-coupled receptor arrestin fluorescence resonance energy transfer bioluminescence resonance energy transfer glucagon-like peptide-1 glucose-dependent insulinotropic polypeptide
Online Access:	https://www.frontiersin.org/article/10.3389/fphar.2020.01271/full

Similar Items

Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and β-arrestins
by: Martina eKocan, et al.
Published: (2011-01-01)

Differential Involvement of ACKR3 C-Tail in β-Arrestin Recruitment, Trafficking and Internalization
by: Aurélien Zarca, et al.
Published: (2021-03-01)

Resonance Energy Transfer Molecular Imaging Application in Biomedicine
by: NIE Da-hong1,2;TANG Gang-hua1,3
Published: (2016-11-01)

The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction
by: Rizvi AA, et al.
Published: (2022-04-01)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
by: Alessia Costa, et al.
Published: (2022-01-01)

Biophysical detection of diversity and bias in GPCR function
by: Werner eJaeger, et al.
Published: (2014-03-01)

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP‐1, GIP receptor agonists, and dual agonists
by: W. Timothy Garvey, et al.
Published: (2024-06-01)

GIP-induced vasodilation in human adipose tissue involves capillary recruitment
by: Meena Asmar, et al.
Published: (2019-06-01)

Developments in FRET- and BRET-Based Biosensors
by: Yuexin Wu, et al.
Published: (2022-10-01)

Integration of Nanomaterials and Bioluminescence Resonance Energy Transfer Techniques for Sensing Biomolecules
by: Eugene Hwang, et al.
Published: (2019-03-01)

The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects
by: Akihiro Hamasaki, et al.
Published: (2024-06-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)

Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354
by: Tayla A. Rees, et al.
Published: (2024-10-01)

Is the Secret in the Gut? SuperJump Activity Improves Bone Remodeling and Glucose Homeostasis by GLP-1 and GIP Peptides in Eumenorrheic Women
by: Sonya Vasto, et al.
Published: (2022-02-01)

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 secretion in humans: Characteristics and regulation
by: Wathik Alsalim, et al.
Published: (2023-03-01)

Roles of glucose‐dependent insulinotropic polypeptide in diet‐induced obesity
by: Yusuke Seino, et al.
Published: (2022-07-01)

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
by: Rouchan Ali, et al.
Published: (2022-09-01)

Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art
by: Szymon Jonik, et al.
Published: (2022-02-01)

The study of metabolic improvement by nutritional intervention controlling endogenous GIP (Mini Egg study): a randomized, cross-over study
by: Naoki Sakane, et al.
Published: (2019-09-01)

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
by: Jang Won Son, et al.
Published: (2024-04-01)

Assessing the Effect of Incretin Hormones and Other Insulin Secretagogues on Pancreatic Beta-Cell Function: Review on Mathematical Modelling Approaches
by: Giovanni Pacini, et al.
Published: (2022-05-01)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
by: Sara Baldassano, et al.
Published: (2019-08-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity
by: Martin Haljeta Friedrichsen, et al.
Published: (2023-12-01)

Detecting and measuring of GPCR signaling – comparison of human induced pluripotent stem cells and immortal cell lines
by: Gaoxian Chen, et al.
Published: (2023-05-01)

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus
by: Sung Hoon Yu, et al.
Published: (2011-02-01)

New glance at pathogenesis of type 2 diabetes mellitus: incretin and antiincretin systems.
by: Ekaterina Alekseevna Shestakova
Published: (2011-09-01)

Receptor-Mediated Bioassay Reflects Dynamic Change of Glucose-Dependent Insulinotropic Polypeptide by Dipeptidyl Peptidase 4 Inhibitor Treatment in Subjects With Type 2 Diabetes
by: Tsuyoshi Yanagimachi, et al.
Published: (2020-04-01)

The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
by: Suleiman Al-Sabah, et al.
Published: (2014-01-01)

TGR5, GLP-1, and GIP expression in diabetic Wistar rats in response to Ficus exasperata vahl leaf extract
by: Olorunsola Israel Adeyomoye, et al.
Published: (2024-08-01)

Secretion of incretin hormones in people having risk factors for type 2 diabetes mellitus
by: E A Shestakova, et al.
Published: (2014-10-01)

α1-adrenoceptor ligands inhibit chemokine receptor heteromerization partners of α1B/D-adrenoceptors via interference with heteromer formation
by: Xianlong Gao, et al.
Published: (2023-04-01)

Serum Levels of Incretin Hormones – GLP-1 and GIP in Patients with Type 1 Diabetes Mellitus
by: Stanchev Pavel E., et al.
Published: (2019-03-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Multiresolution Imaging Using Bioluminescence Resonance Energy Transfer Identifies Distinct Biodistribution Profiles of Extracellular Vesicles and Exomeres with Redirected Tropism
by: Anthony Yan‐Tang Wu, et al.
Published: (2020-10-01)

Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
by: Iona Davies, et al.
Published: (2025-02-01)

BRET-based biosensors for SARS-CoV-2 oligonucleotide detection
by: Asfia Sultana, et al.
Published: (2024-06-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Incretin hormone agonists as promising antiobesity drugs - review of literature
by: Aleksandra Grzegorczyk, et al.
Published: (2025-01-01)

Tirzepatide – a new analogue of incretin hormones
by: Gabriela Anglart, et al.
Published: (2023-10-01)